Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tenacia Signs $266 Million Agreement with Marinus for Seizure Drug

publication date: Nov 17, 2022

Tenacia Biotechnology (Shanghai) in-licensed greater China rights to a seizure therapy from Philadelphia’s Marinus Pharma in a $266 million agreement. Marinus’s Ztalmy® (ganaxolone) oral suspension CV is approved in the US to treat CDKL5 deficiency seizure disorder in patients at least two years old. Tenacia, a CNS company, will make a $10 million upfront payment and pay up to $256 million in milestones, plus royalties. It will have rights to oral and intravenous dose formulations and a right of first negotiation for a future next-gen formulation or prodrug. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital